Treatment for Cardiovascular Disease

Abstract

This invention relates to a method for treating and preventing hypertension by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment. Additionally, the scope of the invention includes a method of treating coronary heart disease by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment.

1 . A method of treating hypertension comprising administering a therapeutically effective amount of an agent, or pharmaceutically acceptable salt thereof, capable of reducing uric acid levels in a patient in need of such treatment. 
   
   
       2 . A method of preventing hypertension comprising administering a therapeutically effective amount of an agent, or pharmaceutically acceptable salt thereof, capable of reducing uric acid levels in a patient in need of such treatment. 
   
   
       3 . A method of treating coronary heart disease comprising administering a therapeutically effective amount of an agent, or pharmaceutically acceptable salt thereof, capable of reducing uric acid levels in a patient in need of such treatment. 
   
   
       4 . A method of treating and preventing eclampsia comprising administering a therapeutically effective amount of an agent, or pharmaceutically acceptable salt thereof, capable of reducing uric acid levels in a patient in need of such treatment. 
   
   
       5 . An agent capable of reducing uric acid levels selected from the group consisting of: gene therapy, a xanthine oxidase inhibitor; a uricosuric agent; supplements of the uricase protein and a urate channel inhibitor, or pharmaceutically acceptable salts, or combinations therefrom. 
   
   
       6 . The agent capable of reducing uric acid levels, as recited in  claim 5 , which is gene therapy that targets the overexpression of uricase. 
   
   
       7 . The agent capable of reducing uric acid levels, as recited in  claim 5 , which is a xanthine oxidase inhibitor selected from the group consisting of: allopurinol, and carprofen, or pharmaceutically acceptable salt thereof. 
   
   
       8 . The agent capable of reducing uric acid levels, as recited in  claim 5 , which is a uricosuric agent selected from the group consisting of: losartan, benzbromarone, benziodarone, probenecid, sulfinpyrazone, ethebencid, orotic acid, ticrynafen and zoxazolamine, or pharmaceutically acceptable salt thereof. 
   
   
       9 . The agent capable of reducing uric acid levels, as recited in  claim 5 , which is a supplement of uricase protein that is delivered as a conjugate with polyethylene glycol or an alternate delivery system. 
   
   
       10 . A pharmaceutical composition comprising a renin angiotensin system (RAS) inhibitor, or pharmaceutically acceptable salt thereof and the agent, or pharmaceutically acceptable salt thereof, capable of reducing uric acid levels as recited in  claim 5 , and a pharmaceutical carrier. 
   
   
       11 . A combination therapy comprising the administration, concomitantly, simultaneously or sequentially, of therapeutically effective amounts of a RAS inhibitor, or pharmaceutically acceptable salt thereof, and the agent, or pharmaceutically acceptable salt thereof, capable of reducing uric acid levels as recited in  claim 5 . 
   
   
       12 . The pharmaceutical composition levels as recited in  claim 10 , further comprising a diuretic, or pharmaceutically acceptable salt thereof. 
   
   
       13 . A combination therapy comprising the administration, concomitantly, simultaneously or sequentially, of therapeutically effective amounts of a combination of a RAS inhibitor, or pharmaceutically acceptable salt thereof with a diuretic, or pharmaceutically acceptable salt thereof and the agent, or pharmaceutically acceptable salt thereof, capable of reducing uric acid levels as recited in  claim 5 .